Buffalo, NY 的 急性髓系白血病 臨床試驗
19 項針對 急性髓系白血病 的研究正在 Buffalo（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
招募中2 期
- Roswell Park Cancer Institute, Buffalo
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- Roswell Park Cancer Institute, Buffalo
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
招募中2 期
- Roswell Park Cancer Institute, Buffalo
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
招募中3 期
- Roswell Park Comprehensive Cancer Center, Buffalo
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
招募中1 期
- Roswell Park Cancer Institute, Buffalo
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
招募中2 期
- Roswell Park Cancer Institute, Buffalo
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
招募中2 期
- Roswell Park Cancer Institute, Buffalo
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
招募中2 期
- Roswell Park Cancer Institute, Buffalo
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
招募中3 期
- Roswell Park Cancer Institute, Buffalo
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
招募中1/2 期
- Roswell Park Comprehensive Cancer Center, Buffalo
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
招募中3 期
- State University of New York at Buffalo, Buffalo
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- Roswell Park Comprehensive Cancer Center, Buffalo
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
招募中2 期
- Roswell Park Cancer Institute, Buffalo
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中觀察性研究
- Roswell Park Cancer Institute, Buffalo
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- Roswell Park Comprehensive Cancer Center, Buffalo
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Roswell Park Comprehensive Cancer Center, Buffalo
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- Roswell Park Comprehensive Cancer Center, Buffalo
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
招募中1 期
- Roswell Park Cancer Institute, Buffalo
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
招募中1 期
- Roswell Park Cancer Institute, Buffalo
其他城市的 急性髓系白血病 試驗
- Houston, TX85 項研究
- New York City, NY51 項研究
- Boston, MA44 項研究
- Seattle, WA41 項研究
- Baldwin Park, CA40 項研究
- Columbus, OH35 項研究
- Philadelphia, PA34 項研究
- Durham, NC33 項研究
- Atlanta, GA31 項研究
- Tampa, FL29 項研究
- Chicago, IL26 項研究
- Portland, OR25 項研究
Buffalo 的其他研究
- 非小細胞肺癌19 項研究
- 癌症（所有類型）19 項研究
- 肺癌16 項研究
- 乳癌16 項研究
- 卵巢癌13 項研究
- 轉移性癌症11 項研究
- 前列腺癌11 項研究
- 黑色素瘤10 項研究
- 多發性骨髓瘤10 項研究
- 肥胖症9 項研究
- 伯基特淋巴瘤8 項研究
- 骨髓增生異常症候群8 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。